|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2009-6-25
|
|
pubmed:abstractText |
Anacetrapib is an orally active, potent inhibitor of cholesteryl ester transfer protein (CETP), which is in development for the treatment of dyslipidaemia. Because of the likely use of anacetrapib with hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, we aimed to evaluate the potential for a pharmacokinetic interaction with simvastatin.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19552746-10513779,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19552746-12236852,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19552746-16353929,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19552746-16574893,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19552746-1789813,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19552746-18068514,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19552746-18536749,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19552746-18580870,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19552746-19004846,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19552746-2502417,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19552746-9728898
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1365-2125
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
67
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
520-6
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19552746-Adolescent,
pubmed-meshheading:19552746-Adult,
pubmed-meshheading:19552746-Cholesterol Ester Transfer Proteins,
pubmed-meshheading:19552746-Cross-Over Studies,
pubmed-meshheading:19552746-Drug Interactions,
pubmed-meshheading:19552746-Drug Therapy, Combination,
pubmed-meshheading:19552746-Female,
pubmed-meshheading:19552746-Humans,
pubmed-meshheading:19552746-Hypolipidemic Agents,
pubmed-meshheading:19552746-Lipoproteins,
pubmed-meshheading:19552746-Male,
pubmed-meshheading:19552746-Middle Aged,
pubmed-meshheading:19552746-Oxazolidinones,
pubmed-meshheading:19552746-Simvastatin,
pubmed-meshheading:19552746-Treatment Outcome,
pubmed-meshheading:19552746-Young Adult
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
|
|
pubmed:affiliation |
Merck & Co., Inc., Whitehouse Station, NJ, USA. rajesh_krishna@merck.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
